Metformin in chemotherapy-naive castration-resistant prostate cancer: A multicenter phase 2 trial (SAKK 08/09)

European Urology

Volumn 66, Issue 3, 2014, Pages 468-474

  Rothermundt, Christian ^a   Hayoz, Stefanie ^b   Templeton, Arnoud J ^a,b   Winterhalder, Ralph ^c   Strebel, Räto T ^d   Bärtschi, Daniela ^b   Pollak, Michael ^e   Lui, Lillianne ^e   Endt, Kathrin ^f   Schiess, Ralph ^f   Rüschoff, Jan H ^g   Cathomas, Richard ^d   Gillessen, Silke ^a  

^a Kantonsspital St Gallen Division of Oncology Haematology   (Switzerland)

^b SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^c LUZERNER KANTONSSPITAL   (Switzerland)

^d KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

^e MCGILL UNIVERSITY   (Canada)

^f Switzerland   (Switzerland)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Castration resistant prostate cancer; Metabolic parameters; Metformin

Indexed keywords

ANTIDIABETIC AGENT; CARRIER PROTEIN; COMPLEMENT FACTOR H; GLUCOSE BLOOD LEVEL; GLYCOPROTEIN; INSULIN; LGALS3BP PROTEIN, HUMAN; METFORMIN; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TUMOR ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; AGED; BLOOD; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ADENOCARCINOMA; AGED; ANTIGENS, NEOPLASM; BLOOD GLUCOSE; CARRIER PROTEINS; COMPLEMENT FACTOR H; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; GLYCOPROTEINS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; METFORMIN; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR MARKERS, BIOLOGICAL;

EID: 84905914439     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.12.057     Document Type: Article

References (32)

1. S. Basaria, D.C. Muller, M.A. Carducci, J. Egan, and A.S. Dobs Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy Cancer 106 2006 581 588
2. N.L. Keating, A. O'Malley, S.J. Freedland, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer J Natl Cancer Inst 104 2012 1518 1523
3. M.R. Smith, H. Lee, and D.M. Nathan Insulin sensitivity during combined androgen blockade for prostate cancer J Clin Endocrinol Metab 91 2006 1305 1308
4. J. Ma, H. Li, and E. Giovannucci et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis Lancet Oncol 9 2008 1039 1047
5. J. Flanagan, P.K. Gray, and N. Hahn et al. Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer Ann Oncol 22 2011 801 807
6. M. Zakikhani, R. Dowling, I.G. Fantus, N. Sonenberg, and M. Pollak Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells Cancer Res 66 2006 10269 10273
7. R.J. Dowling, M. Zakikhani, I.G. Fantus, M. Pollak, and N. Sonenberg Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells Cancer Res 67 2007 10804 10812
8. M. Zakikhani, R.J. Dowling, N. Sonenberg, and M.N. Pollak The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase Cancer Prevent Res 1 2008 369 375
9. D. Margel, D.R. Urbach, and L.L. Lipscombe et al. Metformin use and all-cause and prostate cancer - specific mortality among men with diabetes J Clin Oncol 31 2013 3069 3075
10. P.J. Goodwin, K.I. Pritchard, M. Ennis, M. Clemons, M. Graham, and I.G. Fantus Insulin-lowering effects of metformin in women with early breast cancer Clin Breast Cancer 8 2008 501 505
11. H.Y. Ou, J.T. Cheng, E.H. Yu, and T.J. Wu Metformin increases insulin sensitivity and plasma beta-endorphin in human subjects Horm Metab Res 38 2006 106 111
12. D. Romualdi, B. Costantini, and L. Selvaggi et al. Metformin improves endothelial function in normoinsulinemic PCOS patients: a new prospective Hum Reprod 23 2008 2127 2133
13. N. Goldenberg, C.J. Glueck, M. Loftspring, A. Sherman, and P. Wang Metformin-diet benefits in women with polycystic ovary syndrome in the bottom and top quintiles for insulin resistance Metabolism 54 2005 113 121
14. I. Cima, R. Schiess, and P. Wild et al. Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer Proc Natl Acad Sci U S A 108 2011 3342 3347
15. ICH harmonized tripartite guideline: guideline for good clinical practice J Postgrad Med 47 2001 45 50
16. CTCAE v4.0 open comment period. National Cancer Institute, Cancer Therapy Evaluation Program Web site. http://ctep.cancer.gov/protocolDevelopment/ electronic-applications/ctc.htm
17. H.I. Scher, S. Halabi, and I. Tannock et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
18. D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
19. A.J. Templeton, V. Dutoit, and R. Cathomas et al. Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08) Eur Urol 64 2013 150 158
20. C.J. Ryan, M.R. Smith, and J.S. de Bono et al. Abiraterone in metastatic prostate cancer without previous chemotherapy N Engl J Med 368 2013 138 148
21. E.S. Antonarakis, M.L. Zahurak, J. Lin, D. Keizman, M.A. Carducci, and M.A. Eisenberger Changes in PSA kinetics predict metastasis-free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials Cancer 118 2012 1533 1542
22. G. Colloca Prostate-specific antigen kinetics as a surrogate endpoint in clinical trials of metastatic castration-resistant prostate cancer: a review Cancer Treat Rev 38 2012 1020 1026
23. P.J. Goodwin, M. Ennis, and K.I. Pritchard et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study J Clin Oncol 20 2002 42 51
24. E. Giovannucci Metabolic syndrome, hyperinsulinemia, and colon cancer: a review Am J Clin Nutr 86 2007 s836 s842
25. B.M. Wolpin, J.A. Meyerhardt, and A.T. Chan et al. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer J Clin Oncol 27 2009 176 185
26. M. Pollak The insulin and insulin-like growth factor receptor family in neoplasia: an update Nature Rev Cancer 12 2012 159 169
27. S.M. Firth, and R.C. Baxter Cellular actions of the insulin-like growth factor binding proteins Endocr Rev 23 2002 824 854
28. A.J. Butt, J.L. Martin, K.A. Dickson, F. McDougall, S.M. Firth, and R.C. Baxter Insulin-like growth factor binding protein-3 expression is associated with growth stimulation of T47D human breast cancer cells: the role of altered epidermal growth factor signaling J Clin Endocrinol Metab 89 2004 1950 1956
29. A.A. Lubik, J.H. Gunter, and S.C. Hendy et al. Insulin increases de novo steroidogenesis in prostate cancer cells Cancer Res 71 2011 5754 5764
30. V. Venkateswaran, A.Q. Haddad, and N.E. Fleshner et al. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts J Nat Cancer Inst 99 2007 1793 1800
31. M.L. Zhu, and N. Kyprianou Androgen receptor and growth factor signaling cross-talk in prostate cancer cells Endocr Relat Cancer 15 2008 841 849
32. P.J. Goodwin, M. Ennis, and K.I. Pritchard et al. Insulin- and obesity-related variables in early-stage breast cancer: correlations and time course of prognostic associations J Clin Oncol 30 2012 164 171